Committed to developing innovative cancer therapies, Dendreon is evaluating a variety of therapeutic approaches. While each approach employs a distinct mechanism of action to attack cancer cells, they all share a common attribute—a targeted therapy platform that addresses an unmet medical need, improves the lives of patients and provides a favorable safety and tolerability profile.
Dendreon is developing autologous cellular immunotherapies (ACIs) and small molecules for a variety of cancers.
Dendreon protects its technology through numerous United States and foreign patent filings, trademarks and trade secrets that it owns or licenses. The Company has issued patents or patent applications that are directed to solutions and devices by which cells can be isolated and manipulated, its Antigen Delivery Cassette™ technology, antigen-presenting cell processing and small molecule product candidates.
Print page
Email page